Synaptotagmin-11 deficiency mediates schizophrenia-like behaviors in mice via dopamine over-transmission

突触结合蛋白-11 缺乏通过多巴胺过度传输介导小鼠精神分裂症样行为

阅读:22
作者:Yang Chen #, Yuhao Gu #, Bianbian Wang #, Anqi Wei #, Nan Dong, Yong Jiang, Xiaoying Liu, Li Zhu, Feng Zhu, Tao Tan, Zexin Jing, Fenghan Mao, Yichi Zhang, Jingyu Yao, Yuxin Yang, Hongyan Wang, Hao Wu, Hua Li, Chaowen Zheng, Xueting Duan, Jingxiao Huo, Xuanang Wu, Shaoqin Hu, Anran Zhao, Ziyang Li, X

Abstract

Schizophrenia is a severe neuropsychiatric disease, but the initiation mechanisms are unclear. Although antipsychotics are effective against positive symptoms, therapeutic interventions for negative symptoms are limited due to the lack of pathophysiological mechanisms. Here we identify synaptotagmin-11 (Syt11) as a potential genetic risk factor and dopamine over-transmission as a mechanism in the development of schizophrenia. Syt11 expression is reduced in individuals with schizophrenia but restored following the treatment with antipsychotics. Syt11 deficiency in dopamine neurons in early adolescence, but not in adults, leads to persistent social deficits and other schizophrenia-like behaviors by mediating dopamine over-transmission in mice. Accordingly, dopamine neuron over-excitation before late adolescence induces persistent schizophrenia-associated behavioral deficits, along with the structural and functional alternations in the mPFC. Notably, local intervention of D2R with clinical drugs presynaptically or postsynaptically exhibits both acute and long-lasting therapeutic effects on social deficits in schizophrenia mice models. These findings not only define Syt11 as a risk factor and DA over-transmission as a potential risk factor initiating schizophrenia, but also propose two D2R-targeting strategies for the comprehensive and long-term recovery of schizophrenia-associated social withdrawal.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。